Out of Pocket Getting Out of Hand

In this NEJM Perspective, my (awesome) co-authors and I argue that we need to reduce costs, to patients and society, for drugs that receive ‘accelerated approval’ by the FDA. Drugs, in other words, that still haven’t proven to meaningfully benefit patients.